Mostrar el registro sencillo del ítem
Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece
dc.creator | Voutsas N.T., Papageorgiou E., Tantou A., Dimitriou V.A., Tsironi E.E., Kotoula M. | en |
dc.date.accessioned | 2023-01-31T11:37:16Z | |
dc.date.available | 2023-01-31T11:37:16Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1007/s10792-022-02256-y | |
dc.identifier.issn | 01655701 | |
dc.identifier.uri | http://hdl.handle.net/11615/80757 | |
dc.description.abstract | Introduction: Neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME), and macular oedema due to central retinal vein occlusion (CRVO) are leading causes of vision loss, currently managed with anti-vascular endothelial growth factor injections (anti-VEGF). The aim of this study was to calculate QALYs in patients with nAMD, DME, and CRVO treated with anti-VEGF agents (QALYs+) in a Greek tertiary hospital setting and compare them to theoretical QALYs that the patients would have without treatment (QALYs−). Material and Methods: The study included 143 treatment-naive patients with macular oedema due to nAMD (n = 79), DME (n = 57), and CRVO (n = 7), who received anti-VEGF injections as monotherapy according to the Treat-and-Extend (T&E) protocol. The anti-VEGF agents were ranibizumab and aflibercept in equivalent fractions. QALYs where calculated by the formula QALY = Utility Value × Time, where “Time” refers to the follow-up period of the study. For QALYs−, we assumed that visual acuity remained unchanged during this period. Results: Mean follow-up time was 1.3 ± 1.2 years in the nAMD group, 1 ± 1.3 years in the DME group, and 0.5 ± 1 years in the CRVO group. There was no statistically significant difference between QALYs− and QALYs+ in all three ocular pathologies for the study period (p > 0.05 for each of the three statistical tests performed). Discussion/Conclusion: Possible explanations for the lack of significant difference between QALYs − and QALYs + in nAMD, DME, and CRVO groups, may be the short time horizon used in this analysis, the inclusion of data from the better-seeing eye (BSE) and the specific socio-economic, geographical and health care characteristics of this rural Greek area. © 2022, The Author(s), under exclusive licence to Springer Nature B.V. | en |
dc.language.iso | en | en |
dc.source | International Ophthalmology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128213149&doi=10.1007%2fs10792-022-02256-y&partnerID=40&md5=45ccfc6bec3304f05faaaeed4a2ee4d3 | |
dc.subject | aflibercept | en |
dc.subject | ranibizumab | en |
dc.subject | vasculotropin antibody | en |
dc.subject | angiogenesis inhibitor | en |
dc.subject | bevacizumab | en |
dc.subject | fusion protein | en |
dc.subject | ranibizumab | en |
dc.subject | vasculotropin A | en |
dc.subject | age related macular degeneration | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | central retina vein occlusion | en |
dc.subject | clinical protocol | en |
dc.subject | controlled study | en |
dc.subject | diabetic macular edema | en |
dc.subject | disease association | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | Greece | en |
dc.subject | human | en |
dc.subject | macular edema | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | monotherapy | en |
dc.subject | quality adjusted life year | en |
dc.subject | retrospective study | en |
dc.subject | tertiary care center | en |
dc.subject | visual acuity | en |
dc.subject | visual impairment | en |
dc.subject | diabetes mellitus | en |
dc.subject | diabetic retinopathy | en |
dc.subject | intravitreal drug administration | en |
dc.subject | macular degeneration | en |
dc.subject | quality adjusted life year | en |
dc.subject | retina vein occlusion | en |
dc.subject | Angiogenesis Inhibitors | en |
dc.subject | Bevacizumab | en |
dc.subject | Diabetes Mellitus | en |
dc.subject | Diabetic Retinopathy | en |
dc.subject | Greece | en |
dc.subject | Humans | en |
dc.subject | Intravitreal Injections | en |
dc.subject | Macular Degeneration | en |
dc.subject | Macular Edema | en |
dc.subject | Quality-Adjusted Life Years | en |
dc.subject | Ranibizumab | en |
dc.subject | Recombinant Fusion Proteins | en |
dc.subject | Retinal Vein Occlusion | en |
dc.subject | Vascular Endothelial Growth Factor A | en |
dc.subject | Springer Science and Business Media B.V. | en |
dc.title | Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |